United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond Sells 7,802 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,802 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $345.41, for a total value of $2,694,888.82. Following the sale, the chief financial officer now directly owns 3,210 shares of the company’s stock, valued at $1,108,766.10. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

James Edgemond also recently made the following trade(s):

• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45.

United Therapeutics Price Performance

United Therapeutics stock opened at $342.46 on Wednesday. The company has a market capitalization of $15.24 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 1.25 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08. The stock’s 50 day moving average is $334.93 and its 200-day moving average is $285.50.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The firm had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.24 EPS. Equities research analysts expect that United Therapeutics Co. will post 24.86 EPS for the current year.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of UTHR. International Assets Investment Management LLC raised its position in shares of United Therapeutics by 13,769.2% in the fourth quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock valued at $1,982,000 after buying an additional 8,950 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of United Therapeutics by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 319,030 shares of the biotechnology company’s stock valued at $70,152,000 after acquiring an additional 7,723 shares during the period. Principal Securities Inc. acquired a new stake in shares of United Therapeutics during the 4th quarter worth $198,000. BNP Paribas Financial Markets increased its position in shares of United Therapeutics by 90.3% in the fourth quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock worth $12,200,000 after purchasing an additional 26,325 shares during the period. Finally, Johnson Investment Counsel Inc. acquired a new position in United Therapeutics in the fourth quarter valued at about $275,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of a number of research reports. LADENBURG THALM/SH SH cut United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Wells Fargo & Company lifted their target price on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Bank of America reduced their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. UBS Group lifted their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. Finally, JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, May 21st. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $350.36.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.